Jenburkt Pharmaceuticals Ltd
BSE:524731
Jenburkt Pharmaceuticals Ltd
BSE:524731
Price:
831.9 INR
5.97%
Market Closed
Updated:
Jun 6, 2024
Jenburkt Pharmaceuticals Ltd
Cost of Revenue
|
Jenburkt Pharmaceuticals Ltd
Cost of Revenue Peer Comparison
Comparables:
DRREDDY
CIPLA
SUNPHARMA
ZYDUSLIFE
T
TORNTPHARM
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Jenburkt Pharmaceuticals Ltd
BSE:524731
|
Cost of Revenue
-₹313.2m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-3%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Cost of Revenue
-₹82.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Cost of Revenue
-₹88.2B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-9%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Cost of Revenue
-₹105.3B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-15%
|
|
|
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
|
Cost of Revenue
-₹62.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-9%
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Cost of Revenue
-₹27.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-9%
|
See Also
What is Jenburkt Pharmaceuticals Ltd's Cost of Revenue?
Cost of Revenue
-313.2m
INR
-313.2m
INR
Based on the financial report for Dec 31, 2023, Jenburkt Pharmaceuticals Ltd's Cost of Revenue amounts to -313.2m INR.
What is Jenburkt Pharmaceuticals Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-3%
-3%
Over the last year, the Cost of Revenue growth was 0%. The average annual Cost of Revenue growth rates for Jenburkt Pharmaceuticals Ltd have been -1% over the past three years , 4% over the past five years , and -3% over the past ten years .
You don't have any saved screeners yet
